“Hopeful News About Possible Medications for COVID-19”

From Donna Garner

A table with several different types of pills in it.


[COMMENTS FROM DONNA GARNER:  Please do not miss the 3.13.20 and 3.12.20 articles posted at the bottom of this page in which vital information about chloroquine and its sister drug hydroxychloroquine is given.  Two MedCram videos (#34 and #35) can be accessed which explain just how chloroquine and hydroxychloroquine work. This information was provided to me by an experienced medical doctor in Texas who has been carefully watching the research on these two drugs. His son is an international infectious disease specialist at a major university who has been tracking COVID-19 since its earliest inception.]


3.19.20  -- Fox News

“In coronavirus fight, Trump 'leaving no stone unturned,' Alex Azar says”

By Charles Creitz | Fox News

Excerpts from this article:


The Trump administration's  Coronavirus Task Force has been working to remove bureaucratic barriers between the public and any potential treatments or remedies for the virus, a key member of the panel said Wednesday.

"We've been on this from day one, trying to get the states, local governments, and private labs engaged, removing regulatory barriers," Health and Human Services Secretary  Alex Azar told host Laura Ingraham on  "The Ingraham Angle." 

"Anything that stands in the way, we have been working to get rid of," Azar added.

During the interview, Azar addressed questions about the use of a decades-old and inexpensive anti-malaria pharmaceutical to treat coronavirus.

Ingraham had previously reported [“Thank you, Laura, for promoting over and over on your shows the hopeful information about this drug.”] on a study that examined how hydroxychloroquine and its related drug chloroquine work to treat coronavirus patients.

That study found that use of chloroquine and its tablets is showing favorable outcomes in humans infected with coronavirus, including faster time to recovery and shorter hospital stays, she said Monday.

Ingraham asked Azar on Wednesday whether President Trump is aware of the study and is looking to have the U.S. use drug until a vaccine is potentially developed.

Azar, who formerly served as a top executive at pharma giant Eli Lilly, said Ingraham has done great work publicizing hydroxychloroquine and other potential treatments.

"Let me just assure you, President Trump is absolutely adamant that we leave no stone unturned and bring therapies, cures, vaccines to the American people," he said. "He is going to make sure that even drugs on an experimental basis get available to the American people."

<< snip >>


3.17.20 – University of Minnesota

“COVID-19 Clinical Trial Launches at University of Minnesota”
Author: Kelly Glynn, Media Relations Coordinator

Excerpts from this article:


MINNEAPOLIS, MN- March 17, 2020 – Today, the University of Minnesota is launching a clinical trial on a post-exposure treatment for coronavirus COVID-19 disease.

This trial is testing hydroxychloroquine, an FDA-approved medicine for the prevention and treatment of malaria, available since the 1950s and known as Plaquenil(R). Recent work shows that hydroxychloroquine is active in a laboratory setting against the novel SAS-CoV2 virus, and the trial is designed to see if it translates into benefits for people.

The trial seeks to enroll up to 1,500 people who have had household contact or those who are healthcare workers that have been exposed to someone with known COVID-19 disease within the past three days and who presently are not ill. The trial is national in scope.

In order to determine if taking the medicine hydroxychloroquine can prevent a person with exposure to the coronavirus from becoming ill or in reducing the severity of illness, the trial will provide hydroxychloroquine to half the study participants, while the other half will receive a vitamin.

To be eligible, one must live with someone who has diagnosed coronavirus COVID-19 or be a healthcare worker with a high-risk exposure within the past three days. The research study medicine will be delivered to their home overnight. If you think you may be eligible to participate in the trial, please email covid19@umn.edu  for further instructions.

The trial is being limited to only high-risk exposures, so that the trial may be completed as quickly as possible with the fewest number of volunteers. At this time, people who may have been exposed to coronavirus in the community are currently not eligible to participate.

The University of Minnesota trial seeks research volunteers who have been:


  1. Closely exposed to a person with confirmed COVID-19 disease within three days; AND,
  2. Are a household contact or a healthcare worker; AND,
  3. Do not have current symptoms of COVID-19 disease.


This is a first clinical trial to determine if this medicine is effective in preventing COVID-19 disease in humans. The trial is led by David Boulware, MD, MPH , a professor of Medicine in the Division of Infectious Diseases, with a collaborative team from throughout the University including infectious disease faculty physicians, biostatisticians, pharmacologists and students. The U of M is funding the trial.

“If effective, this may become a worldwide standard of care for helping prevent disease in other healthcare workers and people exposed,” Boulware said. “Hydroxychloroquine is an off-patent, generic medicine that is inexpensive. A five-day treatment course would cost approximately $12.”

<< snip >>

3.18.20 -- Minnesota Daily

“UMN researchers begin three COVID-19 trials, test malaria drug”


This is the first round of clinical trials to use hydroxychloroquine as a possible COVID-19 prevention method.

By Natalie Cierzan

Excerpts from this article:

University of Minnesota researchers opened a clinical trial Tuesday to test a malaria drug that will hopefully prevent COVID-19.

Participants in the randomized study will either receive the malaria medication called hydroxychloroquine or a vitamin placebo.

“We’re looking for up to 3,000 people to enroll, and that’s kind of a moving target,” said Caleb Skipper, a researcher behind the trial and a University infectious disease postdoctoral fellow. “Anyone in the U.S. with a U.S. address would be eligible to be screened for the trial.”

…“Usually a phase 3 randomized trial takes months and months of time to set up … it was approved in one week,” he said.

Potential trial volunteers can determine their eligibility by answering screener questions about their exposure.

The trials will be conducted using a telemedicine method, which means that patients will receive medication and care while the provider is not physically present.

Eligible volunteers will receive their medication in the mail and answer surveys at certain points in their dosage. The most common side effect of hydroxychloroquine is a mild upset stomach.

“We have a lot of experience giving it to healthy people because we used it when people would travel to Africa, per se, and wanted to prevent getting malaria,” Skipper said. The drug has been around since the '50s and exhibits unknown properties such as working on some autoimmune diseases..






Currently, S. Korea ranks number 4 in the world in the number of cases of the corona virus.  A few days ago, S. Korea and Italy were approximately the same. Now Italy has many more cases and many more deaths.  Both have good health care systems.  Italy is in chaos. S. Korea is coping and has the lowest reported mortality in the world.

What is the difference?

In S. Korea an active, aggressive drive through testing program is in place that permits testing-identifying-and doing subsequent case control studies.  So, they identify more people quicker.  In addition, those who test positive are empirically treated with hydroxychloroquine, an anti- malarial drug that has shown amazing viral kill in cell culture.

The proposed mechanism is that the hydroxychloroquine promotes higher levels of zinc in the cells.  The higher level of zinc blocks the RNA virus from hijacking the cells own machinery to make more viral RNA.  It is proved in cell culture.  There are no clinical studies, only the low mortality in S. Korea (0.7%) vs the rest of the world 2-3%.

Here is a great YouTube from MedCram.com #35 that discusses the cell culture data and identifies another product (Quercetin) that serves to open the cells to more zinc -- https://www.youtube.com/watch?v=vE4_LsftNKM